



500 N. Akard Street, Suite 1800  
Dallas, Texas 75201  
Main: 214-965-9900  
Fax: 214-965-0010  
Web: [www.nicholsjackson.com](http://www.nicholsjackson.com)

Robert E. Hager  
Email: [rhager@nicholsjackson.com](mailto:rhager@nicholsjackson.com)

August 8, 2025

***By Email Transmission***

[phoebe.stell@coppelltx.gov](mailto:phoebe.stell@coppelltx.gov)

Phoebe Stell, Interim City Secretary  
255 E. Parkway Boulevard, P.O. Box 9478  
Coppell, Texas 75019

Re: ***Purdue Bankruptcy – ballots to approve or reject the bankruptcy plan of reorganization.***

Dear Phoebe:

Attached with this correspondence is a Resolution and Ballot to Accept or Reject the Thirteenth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma, L.P., and its Affiliated Debtors. You may also have received emails from the Texas Attorney General regarding submission of participation forms for a direct settlement related to Purdue Pharma and the Sackler Family.

The proposed Purdue/Sackler settlement is **two settlements** being implemented in connection with Purdue's bankruptcy proceedings. It consists of settlement of Purdue's claims against the Sacklers (the "Estate Settlement") to be distributed pursuant to a chapter 11 bankruptcy plan, and a settlement of direct claims against the Sacklers held by states, local governments, and other creditors (the "Direct Settlement"). Dollars will flow from both settlements.

For the Direct Settlement, the more political subdivisions that participate, the more funds flow to Texas and its political subdivisions. Any political subdivision that does not participate cannot directly share in any of the Direct Settlement funds. Please note that the Texas Attorney General will be collecting Subdivision Participation Forms for the Direct Settlement through Rubris Inc. Rubris is the Implementation Administrator for the Direct Settlement. The deadline for submission of those forms is September 30, 2025.

Additionally, certain eligible Texas political subdivisions have received ballots to vote on the chapter 11 plan that includes the Estate Settlement. These political subdivisions should follow the applicable instructions for voting. **Voting on the plan is separate from participation in the Direct Settlement, and eligible political subdivisions must separately join the Direct Settlement in order to receive the benefits of the Direct Settlement.**

The Purdue Pharma bankruptcy case, after being overturned by the Supreme Court in 2024, has been revised to remove the non-consensual third-party releases that shielded the Sackler family (Purdue's former owners) from liability claims related to the opioid crisis. Previously, the plan sought to discharge claims against the Sacklers, who were not debtors in the bankruptcy, without the consent of affected claimants.

The new plan, filed on March 18, 2025, and approved by a federal bankruptcy court in June 2025, addresses the concerns raised by the Supreme Court. Here are the key aspects relevant to Class 4 claims:

1. Opt-in settlement: Creditors, including those with Class 4 claims (likely referring to individual victims and related entities), now have the option to release their claims against the Sackler family in exchange for a share of the settlement funds.

2. Preservation of rights: If claimants choose not to opt-in and release their claims against the Sacklers, they can still pursue legal action against them in civil court. However, these claimants will only be eligible for a share of the \$900 million paid by the reorganized Purdue Pharma, not the larger sum contributed by the Sacklers.

3. Settlement funds and distribution:

- a. The total settlement amount, assuming full creditor participation, is expected to exceed \$7.4 billion.
- b. The Sacklers will contribute approximately \$6.5 billion in installments over 15 years, with an initial payment of \$1.5 billion on the effective date of the plan.
- c. Purdue will contribute 100% of its assets, including an estimated \$900 million in cash available for distribution at the time of the emergence from bankruptcy.
- d. A significant portion of the settlement funds will be distributed within the first three years.
- e. The plan allocates more than \$850 million specifically for individual victims if they choose to participate in the settlement.

4. Creation of a public benefit company: Purdue will be liquidated and its assets transferred to a new public benefit company, dedicated to developing and distributing opioid addiction treatment and overdose reversal medications at no profit. This new entity will not involve any ownership or control by the Sackler family.

5. Transparency: The plan includes provisions for a document repository, making millions of documents related to Purdue's historical sales and marketing practices available to the public.


This revised plan attempts to address the legal and ethical concerns surrounding non-consensual third-party release, while still providing compensation to the victims and funding for opioid crisis abatement efforts. It's crucial to note that individual outcomes for Class 4 claimants will depend on their decision to opt-in or pursue individual legal action, and the specific details of their claims.

Please note that the Class 4 Ballot Forms related to the chapter 11 bankruptcy and eventual Estate Settlement is being collected through Kroll Restructuring Administration, LLC. Kroll is the Solicitation Agent for the Class 4 Ballot Forms. The deadline for submission of those forms is September 30, 2025, at 4:00 p.m. EST.

Sincerely,

NICHOLS | JACKSON, L.L.P.

By:



---

Robert E. Hager  
City Attorney

**CITY OF COPPELL, TEXAS**

**RESOLUTION NO. \_\_\_\_\_**

**A RESOLUTION OF THE CITY COUNCIL OF THE CITY OF COPPELL, TEXAS, AUTHORIZING THE CITY MANAGER TO ENTER INTO THE BALLOT FOR VOTING TO ACCEPT OR REJECT THE THIRTEENTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF PURDUE PHARMA L.P. AND ITS AFFILIATED DEBTORS AND AUTHORIZING THE SUBMISSION OF AN E-BALLOT TO ACCEPT OR REJECT THE THIRTEENTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF PURDUE PHARMA L.P. AND ITS AFFILIATED DEBTORS; AND PROVIDING AN EFFECTIVE DATE**

**WHEREAS**, the City of Coppel (the “City”) has received notice that a solicitation agent, on behalf of Purdue Pharma L.P., its general partner Purdue Pharma, Inc., and Purdue Pharma’s wholly owned direct and indirect subsidiaries, as debtors and debtors in possession, is soliciting votes to accept or reject the *Thirteenth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors*, dated March 19, 2025 (the “Plan”); and

**WHEREAS**, the City can accept or reject the Plan by adopting and submitting an E-Ballot on or before September 30, 2025, at 4:00 p.m. (prevailing Eastern Time), attached hereto and incorporated herein by this reference as Exhibit “A” (the “Ballot Form”); and

**WHEREAS**, the City Council of the City of Coppel finds there is a substantial need for participation in the Plan and supports the adoption of the acceptance or rejection of the Plan and finds it in the public interest to participate in voting on such Plan through the Ballot Form.

**NOW, THEREFORE, BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF COPPELL, TEXAS, THAT:**

**SECTION 1.** The City Council of the City of Coppel authorizes the City Manager to ☐ accept/ ☐ reject the Plan.

**SECTION 2.** The City Manager is hereby authorized on behalf of the City to execute, sign, and submit or cause to be submitted said Ballot Form using the City’s Unique E-Ballot ID#, attached hereto and incorporated herein by this reference as Exhibit “A” to Purdue Pharma Ballot Processing c/o Kroll Restructuring Administration LLC online at <https://restructuring.ra.kroll.com/purduepharma> on or before September 30, 2025 at 4:00 p.m. (prevailing Eastern Time).

**SECTION 3.** This Resolution shall become effective immediately upon passage.

**PASSED AND APPROVED THIS \_\_\_\_ DAY OF \_\_\_\_\_, 2025.**

**APPROVED:**

\_\_\_\_\_  
Wes Mays, Mayor

**ATTEST:**

\_\_\_\_\_  
Phoebe Stell, Interim City Secretary

**APPROVED AS TO FORM:**

\_\_\_\_\_  
Robert E. Hager, City Attorney  
4932-1117-5771, v. 1



**Exhibit A**  
**Ballot Form**

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,<sup>1</sup>

Debtors.

)  
) Chapter 11  
)  
) Case No. 19-23649 (SHL)  
)  
) (Jointly Administered)  
)

**BALLOT FOR VOTING TO ACCEPT OR REJECT  
THE THIRTEENTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION  
OF PURDUE PHARMA L.P. AND ITS AFFILIATED DEBTORS**

**CLASS 4: NON-FEDERAL DOMESTIC GOVERNMENTAL CLAIMS**

**Please read and follow the enclosed instructions carefully before completing the ballot. This ballot is being sent to you to solicit your vote on the Debtors' Plan of Reorganization.**

**THIS BALLOT MUST BE COMPLETED, EXECUTED AND RETURNED SO AS TO BE ACTUALLY RECEIVED BY KROLL RESTRUCTURING ADMINISTRATION LLC ("KROLL" OR THE "SOLICITATION AGENT") BY 4:00 P.M. (PREVAILING EASTERN TIME) ON SEPTEMBER 30, 2025 (THE "VOTING DEADLINE").**

The Solicitation Agent, on behalf of Purdue Pharma L.P. ("Purdue Pharma"), its general partner Purdue Pharma Inc., and Purdue Pharma's wholly owned direct and indirect subsidiaries, as debtors and debtors in possession (collectively, the "Debtors"), is soliciting votes to accept or reject the *Thirteenth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors*, dated March 19, 2025 [D.I. 7306] (together with all schedules and exhibits thereto, and as may be modified, amended or supplemented from time to time, the "Plan"<sup>2</sup>) from the Holders of certain Impaired Claims against the Debtors.

You are receiving this ballot (the "Ballot") because our records indicate that you have asserted a Claim against the Debtors as of May 12, 2025 (the "Voting Record Date"). Your Claim

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Purdue Products L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

<sup>2</sup> Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Plan or the Disclosure Statement & Solicitation Procedures Order (as defined herein), as applicable.



192364904290197



is classified under the Plan in Class 4 (Non-Federal Domestic Governmental Claims). Except as otherwise set forth in the Bar Date Order, all timely filed Claims have been deemed filed against the Debtors, and, therefore, you are being solicited to vote to accept or reject the Plan as provided in Item 2 below on account of your Class 4 Claim.

The rights of Holders of Claims in Class 4 are described in the Disclosure Statement for the Plan, filed on March 19, 2025 [D.I. 7307] (together with all schedules and exhibits thereto, and as may be modified, amended or supplemented from time to time, the “Disclosure Statement”) and the Bankruptcy Court’s order approving the Disclosure Statement and related solicitation procedures [D.I. 7615] (the “Disclosure Statement & Solicitation Procedures Order”). The Solicitation Package you are receiving with this Ballot provides instructions detailing how to access electronic versions, request hard copies or request flash-drive format versions of each of the Disclosure Statement & Solicitation Procedures Order as entered by the Bankruptcy Court (without any exhibits), the Disclosure Statement as approved by the Court (with the Plan annexed thereto) and a letter from the Official Committee of Unsecured Creditors (such letter, the “Creditors’ Committee Letter”). If you would like to obtain additional solicitation materials, free of charge, you may contact the Solicitation Agent by (i) visiting the Debtors’ case website at <https://restructuring.ra.kroll.com/purduepharma>; (ii) writing Purdue Pharma Ballot Processing, c/o Kroll Restructuring Administration LLC, 850 3rd Avenue, Suite 412, Brooklyn, NY 11232; (iii) emailing [purduepharmainfo@kroll.com](mailto:purduepharmainfo@kroll.com) (with “Purdue Pharma Solicitation Inquiry” in the subject line) or (iv) calling the Solicitation Agent at (844) 217-0912 (U.S./Canada, toll-free) or +1 (347) 859-8093 (if calling from outside the U.S. or Canada). You may also access these materials for a fee via PACER at <https://www.nysb.uscourts.gov/>.

Pursuant to the Disclosure Statement & Solicitation Procedures Order, the Bankruptcy Court has approved the Disclosure Statement as containing adequate information under section 1125 of the Bankruptcy Code. Bankruptcy Court approval of the Disclosure Statement does not indicate approval of the Plan by the Bankruptcy Court. This Ballot may not be used for any purpose other than to vote to accept or reject the Plan. If you believe that you have received this Ballot in error, please contact the Solicitation Agent at the address or telephone numbers set forth above.

**For your vote to be counted, this Ballot must be properly completed, signed and returned to the Solicitation Agent so that it is actually received by the Solicitation Agent no later than 4:00 p.m. (prevailing Eastern Time) on September 30, 2025.**

If a controversy arises regarding whether any Claim is properly classified under the Plan, the Bankruptcy Court shall, upon proper motion and notice, determine such controversy at the Confirmation Hearing. If the Bankruptcy Court finds that the classification of any Claim is improper, then such Claim shall be reclassified and the Ballot previously cast by the Holder of such Claim shall be counted in, and the Claim shall receive the treatment prescribed in, the Class in which the Bankruptcy Court determines such Claim should have been classified, without the necessity of resoliciting any votes on the Plan. Notwithstanding the fact that your Claim would otherwise satisfy the definition of another type of Claim, or your receipt of a ballot or notice, which identifies your Claim as belonging to a specific Class for voting and distribution purposes, any Claim that satisfies the definition of Co-Defendant Claims under Sections 1.1 and 4.17 of the Plan





shall be a Co-Defendant Claim and any Claim that satisfies the definition of an Other Subordinated Claim under Sections 1.1 and 4.18 of the Plan shall be an Other Subordinated Claim.

If you have any questions on how to properly complete this Ballot, please contact the Solicitation Agent at (844) 217-0912 (U.S./Canada, toll-free) or +1 (347) 859-8093 (international) or by email at [purduepharmainfo@kroll.com](mailto:purduepharmainfo@kroll.com) (with "Purdue Pharma Solicitation Inquiry" in the subject line). You may also contact the Creditors' Committee with any questions at [PurdueCreditorInfo@AkinGump.com](mailto:PurdueCreditorInfo@AkinGump.com). **THE SOLICITATION AGENT AND THE CREDITORS' COMMITTEE ARE NOT AUTHORIZED TO, AND WILL NOT, PROVIDE YOU WITH LEGAL ADVICE.**





**IMPORTANT NOTICE REGARDING CERTAIN RELEASES (INCLUDING THIRD-PARTY RELEASES), EXCULPATION, INJUNCTION AND CHANNELING INJUNCTION PROVISIONS IN THE PLAN:**

Sections 10.6, 10.7, 10.8, 10.9, 10.10, 10.11, 10.12 and 10.13 of the Plan contain release, shareholder release, exculpation, injunction, channeling injunction, MDT Insurer injunction, Settling MDT Insurer injunction and shareholder channeling injunction provisions. Thus, you are advised to review and consider the Plan, the Disclosure Statement and the Creditors' Committee Letter carefully. Below is a summary of the release provisions. For the avoidance of doubt, to the extent any provision of this notice conflicts with the terms of the Plan, the terms of the Plan will control. Capitalized terms used below have the meanings ascribed to such terms in the Plan.

Pursuant to the Plan, certain Releasing Parties are releasing (i) the Released Parties and (ii) the Shareholder Released Parties from certain Claims and Causes of Action.

The Releasing Parties include, collectively, (i) the Supporting Claimants, solely in their respective capacities as such, (ii) the Opt-In Settling Creditors, (iii) the Settling Co-Defendants and (iv) with respect to each of the Persons in the foregoing clauses (i) through (iii), each of their Related Parties to the extent such Releasing Party has the authority under applicable law to grant such release on their behalf, in each case, other than any Shareholder Released Party.

The Released Parties include, collectively, (i) the Debtors, (ii) each of the Debtors' Related Parties, solely in their respective capacities as such, and (iii) solely for purposes of the releases by the Debtors in Section 10.6(a) of the Plan, (A) the Supporting Claimants, the Creditors' Committee and the Creditors' Committee's members and each of their respective professionals, in each case solely in their respective capacities as such and (B) the Settling Co-Defendants and each of their Related Parties, in each case solely in their respective capacities as such; *provided, however*, that, notwithstanding the foregoing or anything herein to the contrary, no Excluded Party or Shareholder Release Snapback Party shall be a Released Party in any capacity or respect. For purposes of this definition of "Released Parties," the phrase "solely in their respective capacities as such" means, with respect to a Person, solely to the extent a claim against such Person (x) arises from such Person's conduct or actions taken in such capacity, or from such Person's identified capacity in relation to another specified Released Party and not, in either case, from such Person's conduct or actions independent of such capacity, and (y) to the extent such Person's liability depends on or derives from the liability of such other Released Party, such claim would be released if asserted against such other Released Party.

The Shareholder Released Parties include the beneficiaries of the separate shareholder release provisions in the Plan. The Plan Supplement will include the Shareholder Settlement, which will provide for, among other things, the settlement of claims against the Shareholder Released Parties.

**Your participation in the Third-Party Releases will be governed by the terms of the Governmental Entity Shareholder Direct Settlement.**

**You are advised to carefully review the Plan, the Disclosure Statement, the Plan Supplement and the Governmental Remediation Trust Documents, which set forth the eligibility requirements and process by which the Governmental Remediation Trust will make payments to Holders of qualified Non-Federal Domestic Governmental Claims. For the avoidance of doubt, to the extent any provision of this notice conflicts with the terms of the Plan, the terms of the Plan will control.**





## INSTRUCTIONS FOR COMPLETING THIS BALLOT

This Ballot is provided to you to solicit your vote to accept or reject the Plan. The terms of the Plan are described in the Disclosure Statement. **PLEASE READ THE PLAN AND THE DISCLOSURE STATEMENT CAREFULLY BEFORE COMPLETING THIS BALLOT.**

The Plan will be accepted by Class 4 if the Plan is accepted by the Holders of at least two-thirds (2/3) in amount and at least one-half (1/2) in number of the Claims in Class 4 that vote on the Plan in such Class. In the event that Class 4 votes to reject the Plan, the Bankruptcy Court may nevertheless confirm the Plan and, thereby, make the Plan binding on the Holders of Claims in Class 4 if the Bankruptcy Court finds that the Plan does not unfairly discriminate against, and accords fair and equitable treatment to, the Holders of Claims in Class 4 and otherwise satisfies the requirements of section 1129(b) of the Bankruptcy Code. If the Plan is confirmed by the Bankruptcy Court, all Holders of Claims against, and Interests in, the Debtors (including those Holders who abstain from voting on or vote to reject the confirmed Plan, and those Holders who are not entitled to vote on the confirmed Plan) will be bound by the confirmed Plan and the transactions contemplated thereunder.

**To have your vote counted, you must complete, sign and return this Ballot so that it is actually received by the Solicitation Agent no later than the Voting Deadline of September 30, 2025 at 4:00 p.m. (prevailing Eastern Time).** Ballots must be delivered to the Solicitation Agent at the appropriate address listed below:

<b>If online by E-Ballot:</b>	<b>If by standard or overnight mail:</b>	<b>If by hand delivery:</b>
Visit <a href="https://restructuring.ra.kroll.com/purduepharma">https://restructuring.ra.kroll.com/purduepharma</a> and click on the "Submit E-Ballot" link.	Purdue Pharma Ballot Processing c/o Kroll Restructuring Administration LLC 850 3rd Avenue, Suite 412 Brooklyn, NY 11232	Purdue Pharma Ballot Processing c/o Kroll Restructuring Administration LLC 850 3rd Avenue, Suite 412 Brooklyn, NY 11232
For your E-Ballot login credentials and further details, please see page 8 below.		If you plan to hand-deliver your Ballot to Kroll's office, please email <a href="mailto:purduepharmaballots@kroll.com">purduepharmaballots@kroll.com</a> (with "Purdue Pharma Ballot Delivery" in the subject line) at least twenty-four (24) hours in advance of your arrival at the Kroll address above to arrange delivery.

**Class 4 Ballots will not be accepted by telecopy, facsimile, email or other electronic means of transmission (other than by E-Ballot).**

You must properly complete the Ballot as follows:

- a. Item 1 (Amount of Claim). Please note that each Claim in Class 4 has been allowed in the amount of \$1.00 for voting purposes only, and not for distribution, allowance or any other purpose.





- b. Item 2 (Vote on the Plan). Cast one vote to accept or reject the Plan by checking the appropriate box in Item 2 below. You must vote the entire amount of your Claim either to accept (i.e., vote in favor of) or reject (i.e., vote against) the Plan and you may not split your vote. Accordingly, any vote within a single Class that attempts partially to accept and partially reject the Plan will not be counted.
- c. If you hold Claims in a Class other than Class 4, you may receive more than one Ballot or Solicitation Package, labeled for a different Class of Claims. Your vote will be counted in determining acceptance or rejection of the Plan by a particular Class of Claims only if you complete, sign and return the Ballot labeled for such Class of Claims in accordance with the instructions on that Ballot.
- d. If more than one timely, properly completed Ballot is received, unless the Holder of the Class 4 Claim receives Bankruptcy Court approval otherwise, then the last properly executed, timely received, valid Ballot will be deemed to reflect that voter's intent and will supersede and revoke any prior Ballot.
- e. If you fail to designate either an acceptance or rejection of the Plan or designate both an acceptance and rejection of the Plan, the Solicitation Agent may, in its discretion, either contact you to attempt to cure the defect or not count your vote as either an acceptance or rejection of the Plan.
- f. Item 3 (Acknowledgments and Certifications). Item 3 contains certain required certifications, which you are making by signing and returning the Ballot. Please ensure that you have read and understood the certifications prior to signing the Ballot and the certifications are correct for your Ballot. Provide your name, mailing address and any remaining information requested in Item 3 below.
- g. If you are completing this Ballot on behalf of another claimant, indicate your relationship with such claimant and the capacity in which you are signing on the appropriate line in Item 3 in the Ballot below. By submitting the Ballot, you are certifying that you have authority to so act and agree to provide documents evidencing such authority upon request (e.g., a power of attorney or a certified copy of board resolutions authorizing you to so act).
- h. Sign and date the Ballot.
- i. If additional space is required to respond to any item on the Ballot, please use additional sheets of paper clearly marked to indicate the applicable item of the Ballot to which you are responding. Do not include medical records with this Ballot. Medical records cannot be returned by the Solicitation Agent.
- j. Deliver the completed, executed Ballot so as to be **actually received** by the Solicitation Agent by the Voting Deadline.





**PLEASE NOTE:**

No Ballot shall constitute or be deemed a Proof of Claim or an assertion of a Claim. No fees, commissions, or other remuneration will be payable for soliciting votes on the Plan.

**NOTHING CONTAINED HEREIN OR IN THE SOLICITATION PACKAGES SHALL RENDER YOU OR ANY OTHER PERSON THE AGENT OF THE DEBTORS OR THE SOLICITATION AGENT, OR AUTHORIZE YOU OR ANY OTHER PERSON TO USE ANY DOCUMENT OR MAKE ANY STATEMENTS ON BEHALF OF THE DEBTORS OR THE SOLICITATION AGENT WITH RESPECT TO THE PLAN, EXCEPT FOR THE STATEMENTS CONTAINED IN THE SOLICITATION PACKAGES.**

**IF THE DEBTORS' PLAN OF REORGANIZATION IS CONFIRMED BY THE BANKRUPTCY COURT, IT WILL BE BINDING ON YOU WHETHER OR NOT YOU HAVE VOTED TO ACCEPT OR REJECT THE DEBTORS' PLAN OF REORGANIZATION (EXCEPT AS OTHERWISE PROVIDED IN THE PLAN).**

**IF YOU (A) HAVE ANY QUESTIONS REGARDING THE BALLOT, (B) DID NOT RECEIVE A RETURN ENVELOPE WITH YOUR BALLOT, OR (C) NEED ADDITIONAL COPIES OF THE BALLOT OR OTHER ENCLOSED MATERIALS, PLEASE CONTACT THE SOLICITATION AGENT AT 844-217-0912 (U.S./CANADA, TOLL-FREE) OR +1 347-859-8093 (INTERNATIONAL), OR BY EMAILING [PURDUEPHARMAINFO@KROLL.COM](mailto:PURDUEPHARMAINFO@KROLL.COM) (WITH "PURDUE PHARMA SOLICITATION INQUIRY" IN THE SUBJECT LINE). PLEASE DO NOT DIRECT ANY INQUIRIES TO THE BANKRUPTCY COURT. YOU MAY ALSO CONTACT THE CREDITORS' COMMITTEE WITH ANY QUESTIONS AT [PURDUECREDITORINFO@AKINGUMP.COM](mailto:PURDUECREDITORINFO@AKINGUMP.COM). THE SOLICITATION AGENT AND THE CREDITORS' COMMITTEE ARE NOT AUTHORIZED TO, AND WILL NOT, PROVIDE YOU WITH LEGAL ADVICE.**





**SUBMITTING BY E-BALLOT**

**PLEASE COMPLETE THE FOLLOWING:**

To submit your Ballot via the “E-Ballot” platform, please visit <https://restructuring.ra.kroll.com/purduepharma>. Click on the “Submit E-Ballot” section of the website and follow the instructions to submit your Ballot.

**IMPORTANT NOTE:** You will need the following information to retrieve and submit your customized E-Ballot:

Unique E-Ballot ID#: BMJM-5MHR-PCW5-QES5

The Solicitation Agent’s “E-Ballot” platform is the sole manner in which your Ballot will be accepted via electronic or online transmission. Ballots submitted by telecopy, facsimile, email or other electronic means of transmission will not be counted.

Each E-Ballot ID# is to be used solely for voting only those Claims described in Item 1 of your E-Ballot. Please complete and submit an E-Ballot for each E-Ballot ID# you receive, as applicable.

Holders who cast a Ballot using the Solicitation Agent’s “E-Ballot” platform should NOT also submit a paper Ballot.





## CLASS 4 BALLOT

### PLEASE COMPLETE THE FOLLOWING:

**Item 1. Amount of Class 4 Claims.** Please note that each Claim in Class 4 has been allowed in the amount of \$1.00 for voting purposes only, and not for purposes of ultimate "Allowance" of a Claim, distribution of value under the Plan or for any other purpose. For the avoidance of doubt, the \$1.00 amount at which a Claim has been allowed for voting purposes does not impact the payment that a Holder of a Class 4 Claim may receive.

<b>Claims Amount:</b> \$1.00
------------------------------

**Item 2. Vote on the Plan.** The undersigned Holder of Class 4 Claims hereby votes to (*check only one box*):

- ☐ **ACCEPT (I.E., VOTE IN FAVOR OF)** the Plan
- ☐ **REJECT (I.E., VOTE AGAINST)** the Plan

**Item 3. Acknowledgments and Certification.** By signing this Ballot, the undersigned certifies and/or acknowledges that:

- (a) either the undersigned is: (i) the Holder of the Class 4 Claims being voted; or (ii) an authorized signatory for a person or entity that is a Holder of the Class 4 Claims being voted, and, in either case, has the full power and authority to vote to accept or reject the Plan with respect to the Claims identified in Item 1 above;
- (b) the undersigned has been provided with a copy of the Disclosure Statement, including the Plan and all other exhibits thereto, the Disclosure Statement & Solicitation Procedures Order without exhibits and a Confirmation Hearing Notice;
- (c) the solicitation of votes is subject to all terms and conditions set forth in the Plan, Disclosure Statement & Solicitation Procedures Order and the procedures for the solicitation of votes to accept or reject the Plan contained therein;
- (d) the undersigned has cast the same vote with respect to all of its Class 4 Claims; and
- (e) no other Ballots with respect to the amount of the Class 4 Claims identified in Item 1 above have been cast or, if any other Ballots have been cast with respect to such Claims, then any such earlier Ballots are hereby revoked.





Name of Claimant: City of Coppell, Texas

Signature: \_\_\_\_\_

Name of Signatory  
(if different than Claimant): \_\_\_\_\_

If authorized by Agent, Title of Agent: \_\_\_\_\_

Street Address: \_\_\_\_\_

Street Address:  
(continued) \_\_\_\_\_

City, State, Zip Code: \_\_\_\_\_

Telephone Number: \_\_\_\_\_

Email Address: \_\_\_\_\_

Date Completed: \_\_\_\_\_







192364904290197



+++Project Windsor 2325 SRF 89428 ADRID: 7355974 Pack ID: 4-0543

City of Coppell, Texas

M. Shelby Percy

NJDHS

500 N. Akard, 1800 Ross Tower

Dallas TX 75201



192364904290197